An ongoing clinical trial (NCT03222674) evaluates the feasibility, safety, and efficacy of multi-CAR-T cell therapy that targets different AML surface antigens (Muc1/CLL1/CD33/CD38/CD56/CD123) in patients with relapsed/refractory AML. The gene discussed is CD38; the disease is acute myeloid leukemia.